- Liverpool School of Tropical Medicine (LSTM) and self-funded charitable medical research organisation, LifeArc, are partnering to launch a new Translational Development Fund to help tackle infectious diseases.
- LifeArc will invest £2.7 million into the fund, which will support the progression of new technologies and treatments for emerging viral threats and neglected tropical diseases.
- LifeArc will also join the LSTM-led Infection Innovation Consortium: iiCON, making its platform to progress antibody-based treatments available to partners.
- The partnership aims to help address the urgent need for new approaches to infectious diseases, which cause millions of deaths globally each year, with numbers escalating due to factors such as climate change.
Liverpool, UK
Liverpool School of Tropical Medicine (LSTM) has entered into a partnership with the self-funded charitable medical research organisation, LifeArc, which will join the LSTM-led Infection Innovation Consortium: iiCON and establish a £2.7m Translational Development Fund.
The research fund is being set up in response to a growing need for new and innovative treatments and diagnostic technologies to help tackle growing threats to health across the globe, including neglected tropical diseases and emerging viral threats.
The COVID pandemic highlighted the impact new viruses can have on our society and this new fund will support the progression of potential interventions, including diagnostics, treatments and devices. Infectious diseases currently cause millions of deaths globally each year with the impact expected to worsen due to factors such as climate change, migration and intensive farming.
The fund will be available to LSTM and iiCON partners and their collaborators, including research organisations in low- and middle- income countries (LMICs), and will have a focus supporting interventions that are appropriately aligned with deployment and treatment of patients in LMICs.
As well as the fund investment, LifeArc will make its antibody humanisation platform available to iiCON and its collaborators, to support the development of new potential treatments. Antibodies can trigger the immune system to help treat disease, and this platform enables promising antibodies from lab research to be modified, so that they can be used in people. LifeArc's expertise and track record of success has helped transform the way many conditions are treated, with more than 90 antibodies humanised over the past 30 years, contributing to five licenced medicines.
LifeArc's expertise will be made available commercially to any organisation domestically or internationally via a new platform at iiCON. This platform has been designed to provide partners and researchers in the field with streamlined access to LifeArc's leading capabilities.
iiCON is a consortium led by LSTM with core partners including LifeArc, Unilever, Evotec, Liverpool University Hospitals Foundation Trust, University of Liverpool, and Infex Therapeutics. The c£250 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and innovations- saving and improving millions of lives through collaborative innovation.
Professor David Lalloo, Director of Liverpool School of Tropical Medicine said: "This Translational Development Fund will not only help us to tackle the true diseases of poverty that impact the lives of some of the world's poorest communities, but also allow us to prepare for the emerging threats of the future. This partnership between LSTM, LifeArc and iiCON will provide a number of significant opportunities for businesses, researchers and clinicians working in the antibody humanisation space and beyond. Facilitating access to advanced capabilities and new collaborations in this way will be a real boost to getting new therapies to market by helping overcome development obstacles and unlocking the potential of new innovations."
Professor Janet Hemingway, Founding Director of the Infection Innovation Consortium: iiCON, said: "Working with LifeArc to create a new platform focused on antibody humanisation marks an exciting milestone for both iiCON and for the development of tomorrow's medical therapies. Our approaches to infectious disease research, prevention, and control are very closely aligned and we're looking forward to seeing the vital breakthroughs that this collaboration will progress.
"The partnership with LifeArc underlines a core aspect of our mission at iiCON, which is to connect the dots across the health and life sciences sector to ensure that the best ideas and the newest technologies get the support they need to achieve significant, real-world results."
Dr Mike Strange, Head of Global Health at LifeArc, said: 'LifeArc is committed to investing over £100 million in global health, with a focus on infectious diseases, over the coming years. We are delighted that partnering with LSTM and iiCON is part of this. The consortium's aim of accelerating the discovery and development of innovative new treatments, diagnostics, and preventative products for infectious diseases, aligns with our own global health strategy. It also mirrors the remit of LifeArc - using translational science to turn lab-based discoveries into medical breakthroughs that can be life-changing for patients."
"Our work in antibodies has had real impact for patients in other areas and we are pleased that we will also be able offer this platform and expertise to iiCON partners. We look forward to seeing what we can achieve together over the coming years."
ENDS
Notes to Editors
About LifeArc
LifeArc is a self-funded, charitable medical research organisation. We take science ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. We have been doing this for more than 25 years and our work has contributed to five licensed medicines, including cancer drug pembrolizumab.
Our teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property. Our work is in translational science - bridging the gap between academic research and clinical development, providing funding, research and expert knowledge, all with a clear and unwavering commitment to having a positive impact on patient lives.
LifeArc is committed to investing up to £1.3 billion by 2030 in areas of high unmet medical need. www.lifearc.org.
LifeArc is a company limited by guarantee (registered in England and Wales under no. 2698321) and a charity (registered in England and Wales under no. 1015243 and in Scotland under no. SC037861).
About LSTM
Liverpool School of Tropical Medicine
About iiCON: Infection Innovation Consortium
iiCON is a global collaborative infectious disease R&D programme established in 2020. Founded with government funding provided through UK Research and Innovation's flagship Strength in Places Fund, it brings together industry, academia, and the NHS in a concerted effort with a clear aim: to combat the growing global threat posed by infectious diseases and save lives through collaborative innovation.
Led by Liverpool School of Tropical Medicine, our consortium partners Unilever, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, LifeArc, and Infex Therapeutics are working on number of innovative and ambitious programmes across iiCON's ten specialist research platforms.
Learn more: www.lnfectionInnovation.com
Follow us on Twitteror Join the conversation on LinkedIn
For further press information please contact:
Consilium Strategic Communications
Tracy Cheung, David Daley, Lindsey Neville
LifeArc@consilium-comms.com
Tel: +44 (0) 20 3709 5700
